Amgen experienced notable upward momentum driven primarily by positive analyst commentary and optimistic third-quarter financial forecasts. Equity research firms, including Truist Securities, raised price targets while projecting third-quarter revenue and adjusted earnings per share that comfortably exceed Wall Street consensus estimates. Analysts pointed to robust commercial execution across key growth franchises such as Tezspire, Tepezza, and Repatha, alongside expanding lifecycle potential for oncology treatment Imdelltra, as core drivers of revenue outperformance.

Underpinning this analyst enthusiasm is accelerating momentum across Amgen’s clinical pipeline. Recent positive Phase 3 trial results for dazodalibep in systemic…